PharmaShots Weekly Snapshots (September 09 – September 13, 2024)
This week PharmaShots’ news was all about the updates on Clinical Trials, Pharma, Biotech, COVID-19, Regulatory & MedTech. Check out our full report below:
Merck & Daiichi Sankyo Report the P-II (IDeate-Lung01) Study Data of Ifinatamab Deruxtecan to Treat Extensive-Stage Small Cell Lung Cancer
Read More: Merck & Daiichi Sankyo
Johnson & Johnson Reports New Long-Term Data from P-III (MARIPOSA) Trial of Rybrevant Plus Lazcluze for Advanced NSCLC
Read More: Johnson & Johnson
Savara Highlights New P-III (IMPALA-2) Study Data of Molgramostim to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at ERS 2024
Read More: Savara
Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024
Read More: Akeso
GSK Highlights Full Results from the P-III (SWIFT-1 and SWIFT-2) Trials of Depemokimab for Treating Severe Asthma at ERS 2024
Read More: GSK
Phanes Therapeutics Reports the First Patient Dosing with PT886 in P-I/II Study for Pancreatic and Gastric Cancer
Read More: Phanes Therapeutics
AstraZeneca & Daiichi Sankyo Highlight the P-III (TROPION-Lung01) Study Data of Datopotamab Deruxtecan (Dato-DXd) to Treat Non-Squamous NSCLC at WCLC 2024
Read More: AstraZeneca & Daiichi Sankyo
Bayer Highlights New Results from the P-I/II Trial of BAY 2927088 for Non-Small Cell Lung Cancer at WCLC 2024
Read More: Bayer
Eli Lilly Reports Detailed Results from the P-III (QWINT-2 & 5) Trials of Insulin Efsitora Alfa (Efsitora) for Type 1 & 2 Diabetes at EASD 2024
Read More: Eli Lilly
GSK Reports P-I/II Study Updates of GSK3943104 HSV Vaccine
Read More: GSK
Sanofi Reports the P-III (LIBERTY-CUPID Study C) Trial Data of Dupixent to Treat Chronic Spontaneous Urticaria (CSU)
Read More: Sanofi
Bayer Reports the P-III (OASIS 3) Trial Data of Elinzanetant to Treat Vasomotor Symptoms in Postmenopausal Women
Read More: Bayer
GSK Reports Headline Data from P-II Study of Seasonal Influenza mRNA Vaccine
Read More: GSK
Merck Reports Top-line Data from the P-III (V503-064) Study of Gardasil 9 in Japanese Males
Read More: Merck
Neurocrine Biosciences Provides P-II (ERUDITE) Study Updates of Luvadaxistat for Cognitive Impairment Associated with Schizophrenia
Read More: Neurocrine Biosciences
Cartesian Therapeutics’ Descartes-08 Gains the US FDA’s Rare Pediatric Disease Designation to Treat Juvenile Dermatomyositis
Read More: Cartesian Therapeutics
BridgeBio’s BBP-812 Gains the US FDA’s Regenerative Medicine Advanced Therapy Designation for Canavan Disease
Read More: BridgeBio
Johnson & Johnson Reports the US FDA’s Approval of Tremfya to Treat Ulcerative Colitis
Read More: Johnson & Johnson
Neuraptive Therapeutics’ NTX-001 Gains the US FDA’s Breakthrough Therapy Designation to Treat Peripheral Nerve Injury Requiring Repair
Read More: Neuraptive Therapeutics
Roche’s Tecentriq Hybreza Receives the US FDA’s Approval for Cancer Treatment
Read More: Roche
GSK’s Blenrep Combination Gains the NMPA’s Breakthrough Therapy Designation to Treat R/R Multiple Myeloma
Read More: GSK
Merck reports the Health Canada’s Approval of Keytruda to Treat MSI-H or dMMR Solid Tumors
Read More: Merck
Circle Pharma Features Preclinical Results of CID-078 at the WCLC 2024
Read More: Circle Pharma
Scientist.com Collaborates with Evotec to Expedite Drug Discovery and Development
Read More: Scientist.com & Evotec
Enigma Biomedical - USA Partners with Alamar Biosciences to Advance the Diagnostics for Neurodegenerative Diseases
Read More: Enigma Biomedical & Alamar Biosciences
Alopexx Partners with Bharat Biotech to Co-Develop and Commercialize AV0328 Anti-Microbial Vaccine
Read More: Alopexx & Bharat Biotech
Sanofi, RadioMedix and Orano Med Join Forces to Develop AlphaMedix (212Pb-Dotamtate) for Rare Cancer Treatment
Read More: Sanofi, RadioMedix & Orano Med
ITM Isotope Technologies Munich and Debiopharm Partner to Develop ITM-91/ITM-94D Theranostic Pair for Solid Tumors
Read More: ITM Isotope Technologies Munich & Debiopharm
Marengo Therapeutics Partners with Gilead to Conduct Clinical Trial of Invikafusp alfa Plus Trodelvy for Metastatic TNBC and Breast Cancers
Read More: Marengo Therapeutics & Gilead
Alex Therapeutics and Navamedic Collaborate to Develop a Companion App for Parkinson’s Disease
Read More: Alex Therapeutics & Navamedic
Related Post: PharmaShots Weekly Snapshots (September 02 – September 06, 2024)
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
